Flu A Flu B Saliva Rapid Viral Antigen Test 20 Test/Kit

SARS-CoV-2/Flu A/Flu B Saliva Antigen

Rapid Test (Colloidal Gold Method) V8003

Product Name

SARS-CoV-2/Flu A/Flu B Saliva Antigen Rapid Test (Colloidal Gold Method)

Catalog No.: V8003

Specification: 1 test/kit, 5 tests/kit, 20 tests/kit

Intended Use

This Kit is an immunochromatographic assay for rapid, qualitative detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A and influenza B antigens in saliva samples. The test is applicable to people with contact history, asymptomatic and symptoms of Covid-19 or influenza. It is mainly for screening samples at the initial stage of symptoms (0 to 7 days) after infection of SARA-CoV-2. Influenza A or Influenza B is applicable to people who have been exposed to influenza virus. The group with symptoms of influenza A/B disease, mainly for sample screening at the initial stage of symptoms (0 to 14 days) after infection.

The test provides preliminary test results. Negative results don’t preclude SARS-CoV-2, influenza A and influenza B virus infection and they cannot be used as the sole basis for treatment or other management decision.

Summary

The novel coronaviruses belong to the β genus. COVID-19 is an acute respiratory infectious disease. People are generally susceptible. Currently, the patients infected by the novel coronavirus are the main source of infection; asymptomatic infected people can also be an infectious source. Based on the current epidemiological investigation, the incubation period is 1 to 14 days, mostly 3 to 7 days. The main manifestations include fever, fatigue and dry cough. Nasal congestion, runny nose, sore throat, myalgia and diarrhea are found in a few cases.

Influenza, commonly called "flu", is an acute respiratory infectious disease caused by influenza viruses. It is highly contagious. It is spread mainly through coughing and sneezing. It usually breaks out in spring and winter. Divided into influenza A virus, influenza B virus and influenza C virus. Influenza A virus has strong variability, followed by influenza B virus, and influenza C virus is very stable. Therefore, influenza A virus is more prevalent and severe than influenza B virus.

Principle of Detection

This reagent is based on the principle of Immunochromatography sandwich-like assay for detection of SARS-CoV-2, influenza A and influenza B virus antigen in the saliva specimens. When specimen is absorbed into the device by capillary action, it will mix with the antibodies colloidal conjugate and flows across the pre-coated membrane.

When the antigen level in the specimen is at or above the target cutoff (the detection limit of the test), the antigen bound to the antibody colloidal conjugate are captured by the corresponding antibody immobilized in different Test Region (T) of the device, and this produces a colored test band that indicates a positive result. When the antigen level in the specimen is zero or below the target cutoff, there is not a visible colored band in the corresponding Test Region (T) of the device. This indicates a negative result.

To serve as a procedure control, a colored line will appear at the Control Region (C), if the test has been performed properly.

Main Components

Antigen-Testverfahren

Method I

Method II

Dongsheng Biotech Co., Ltd takes PCR technology as its core, and its products focus on common PCR, qPCR, nucleic acid detection and other fields. Adhering to the quality policy of "unremitting pursuit of continuous innovation, leading technology and customer satisfaction", we provide our customers with cost-effective molecular biology products.